UCLA is an internationally renowned leader in the diagnosis, treatment and research of pulmonary vascular diseases, including pulmonary hypertension (PH), chronic thromboembolic disease (CTEPH), and acute pulmonary embolism (PE). Led by Richard Channick, MD and Rajan Saggar, MD, our Pulmonary Vascular Disease Program includes experts in pulmonary disease, cardiology, cardiothoracic surgery and interventional radiology, who collaborate to provide state of the art care for patients with these conditions. About Us >
CTEPH is a form of pulmonary hypertension caused by the formation of scar-like tissue due to chronic (old) blood clots the in arteries of the lungs. This condition, although potentially curable, is often undiagnosed for years. Our program offers highly specialized treatment options that are only available in a handful of centers around the world, and include, pulmonary thromboendarterectomy (PTE) surgery and balloon pulmonary angioplasty (BPA). Learn more about CTEPH >
PAH is defined as increased pressure in the vessels due to obstruction in the small arteries in the lungs. The causes of PAH can vary; thus expertise is required in making the diagnosis and determining optimal treatment. Fortunately, several effective treatments are now available, including medication and lung transplantation. The UCLA Pulmonary Vascular Program has led the way in development of these therapies, and continues to do cutting edge research to test new treatments. Learn more about PAH >
PE/DVT refers to a blood clot that develops, often suddenly and may travel from the veins in the legs to the lungs. Acute PE is the third most common cause of death from cardiovascular disease after heart attack and stroke. The UCLA Pulmonary Embolism Response Team (PERT), a concept initially created by Dr. Richard Channick and instituted at UCLA by Dr. John Moriarty, is a consultative multidisciplinary team who meets to identify and provide comprehensive, rapid treatments and long-term management plans. All potential treatment options are at our disposal at UCLA. Learn Learn more about PE/DVT >
The invasive Cardiopulmonary Exercise Testing (iCPET) laboratory at UCLA provides comprehensive testing for patients to determine the cause of exercise limitation. Patients with a variety of heart and lung conditions can experience limited exercise capacity caused by the complex interaction between the heart, lungs, and muscles. Available at only a handful of centers in the country, level 3 (invasive) CPET has emerged as the gold standard test to define causes of shortness of breath when non-invasive tests are not able to provide a diagnosis.
Learn more about the iCPET laboratory >
310-825-0527 Phone
310-206-4930 Fax
Pulmonary Vascular Disease Program Clinic
200 Medical Plaza, Suite 365 B, Los Angeles, CA 90095
Ronald Reagan UCLA Medical Center
757 Westwood Plaza, Los Angeles, CA 90095
